What is it about?
Due to the rising antibiotic resistance, there is a dire need for development of novel antimicrobials. We report here a two-component lantibiotic termed as Roseocin, comprising of two synergistically acting peptides, for the first time from an Actinomycete instead of Firmicutes. It displays antimicrobial activity against important drug-resistant pathogens.
Featured Image
Photo by Kyle Ellefson on Unsplash
Why is it important?
New drugs are required for combating rising antimicrobial drug resistance. These novel peptides target the high priority pathogenic bacteria recognized by World Health Organization.
Perspectives
It was amazing to know that the two peptides are partners, they are generated by the bacteria from their respective genes, but don't work separately. When combined together they kill the target pathogenic bacteria.
Mangal Singh
Panjab University
Read the Original
This page is a summary of: Roseocin, a novel two‐component lantibiotic from an actinomycete, Molecular Microbiology, November 2019, Wiley,
DOI: 10.1111/mmi.14419.
You can read the full text:
Resources
Raw data
Raw data for Roseocin work
Streptomyces roseosporus
Roseocin is produced by Streptomyces roseosporus, a soil bacteria which produces many other natural products including Daptomycin
Semi-in vitro Reconstitution of Roseocin, a Two-Component Lantibiotic from an Actinomycete
Non-peer reviewed pre-print published on bioRxiv with partial work.
Streptomyces roseosporus liquid culture
Streptomyces roseosporous NRRL 11379 ISP2 broth culture
Future studies on roseocin
Funding for structure-activity relationship study of roseocin
Contributors
The following have contributed to this page
